EA201990413A1 - Способ лечения печеночной энцефалопатии - Google Patents
Способ лечения печеночной энцефалопатииInfo
- Publication number
- EA201990413A1 EA201990413A1 EA201990413A EA201990413A EA201990413A1 EA 201990413 A1 EA201990413 A1 EA 201990413A1 EA 201990413 A EA201990413 A EA 201990413A EA 201990413 A EA201990413 A EA 201990413A EA 201990413 A1 EA201990413 A1 EA 201990413A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- hepatic encephalopathy
- treating hepatic
- treating
- encephalopathy
- biotin
- Prior art date
Links
- 208000007386 hepatic encephalopathy Diseases 0.000 title abstract 2
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 abstract 2
- 229960002685 biotin Drugs 0.000 abstract 1
- 235000020958 biotin Nutrition 0.000 abstract 1
- 239000011616 biotin Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Nutrition Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Physiology (AREA)
- Inorganic Chemistry (AREA)
- Polymers & Plastics (AREA)
- Psychiatry (AREA)
- Food Science & Technology (AREA)
- Mycology (AREA)
- Hospice & Palliative Care (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16305989.2A EP3275439A1 (en) | 2016-07-29 | 2016-07-29 | Method for treating hepatic encephalopathy |
| PCT/EP2017/069194 WO2018020010A1 (en) | 2016-07-29 | 2017-07-28 | Method for treating hepatic encephalopathy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201990413A1 true EA201990413A1 (ru) | 2019-06-28 |
Family
ID=56618106
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201990413A EA201990413A1 (ru) | 2016-07-29 | 2017-07-28 | Способ лечения печеночной энцефалопатии |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US10117854B2 (OSRAM) |
| EP (2) | EP3275439A1 (OSRAM) |
| JP (1) | JP2019522030A (OSRAM) |
| KR (1) | KR20190034550A (OSRAM) |
| AU (1) | AU2017303346A1 (OSRAM) |
| BR (1) | BR112019001178A2 (OSRAM) |
| CA (1) | CA3031302A1 (OSRAM) |
| CY (1) | CY1122348T1 (OSRAM) |
| DK (1) | DK3319601T3 (OSRAM) |
| EA (1) | EA201990413A1 (OSRAM) |
| ES (1) | ES2751154T3 (OSRAM) |
| HK (1) | HK1254833B (OSRAM) |
| HR (1) | HRP20191798T1 (OSRAM) |
| HU (1) | HUE046590T2 (OSRAM) |
| IL (1) | IL264460B (OSRAM) |
| LT (1) | LT3319601T (OSRAM) |
| MA (1) | MA42419B1 (OSRAM) |
| ME (1) | ME03520B (OSRAM) |
| PL (1) | PL3319601T3 (OSRAM) |
| PT (1) | PT3319601T (OSRAM) |
| RS (1) | RS59300B1 (OSRAM) |
| SI (1) | SI3319601T1 (OSRAM) |
| SM (1) | SMT201900628T1 (OSRAM) |
| WO (1) | WO2018020010A1 (OSRAM) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3275439A1 (en) * | 2016-07-29 | 2018-01-31 | Medday Pharmaceuticals | Method for treating hepatic encephalopathy |
| MX387893B (es) * | 2018-04-18 | 2025-03-19 | Alparis Sa De Cv | Nuevas fases solidas de rifaximina. |
| CN116173182A (zh) * | 2023-03-31 | 2023-05-30 | 苏州融析生物科技有限公司 | 醋酸格拉替雷药物组合物在肝硬化预防及治疗药物中的应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0788304B2 (ja) * | 1988-03-05 | 1995-09-27 | 三生製薬株式会社 | 高アンモニア血症治療剤 |
| US5814650A (en) * | 1992-09-28 | 1998-09-29 | Lifegroup S.P.A. | Biotin amides able to control glucidic metabolisms under dysmetabolic conditions and relative therapeutical compositions |
| DE20202562U1 (de) * | 2002-02-19 | 2002-05-23 | Orthomol pharmazeutische Vertriebs GmbH, 40764 Langenfeld | Mikronährstoffkombinationsprodukt mit Pro- und Prebiotika |
| US20040219188A1 (en) * | 2003-05-02 | 2004-11-04 | Comer Gail M. | Composition and methods for nutritional management of patients with hepatic disease |
| BR112012015084A2 (pt) | 2009-12-23 | 2017-03-07 | Lupin Ltd | composição farmacêutica de liberação lenta de iloperidone |
| FR2993780B1 (fr) * | 2012-07-26 | 2015-02-13 | Assist Publ Hopitaux De Paris | Methode de traitement de la sclerose en plaque |
| FR2958166B1 (fr) | 2010-04-06 | 2012-07-13 | Assist Publ Hopitaux De Paris | Compositions pharmaceutiques fortement dosees en biotine |
| WO2014177286A1 (en) | 2013-04-29 | 2014-11-06 | Assistance Publique - Hopitaux De Paris | Biotin for use in treating x-linked adrenoleukodystrophy |
| EP3072513A1 (en) | 2015-03-26 | 2016-09-28 | Medday | Biotin for treating Amyotrophic lateral sclerosis |
| CN105614851A (zh) * | 2015-12-27 | 2016-06-01 | 劲膳美生物科技股份有限公司 | 肝性脑病医学配方食品 |
| EP3275439A1 (en) * | 2016-07-29 | 2018-01-31 | Medday Pharmaceuticals | Method for treating hepatic encephalopathy |
-
2016
- 2016-07-29 EP EP16305989.2A patent/EP3275439A1/en not_active Ceased
-
2017
- 2017-07-28 PL PL17742782T patent/PL3319601T3/pl unknown
- 2017-07-28 EP EP17742782.0A patent/EP3319601B1/en active Active
- 2017-07-28 CA CA3031302A patent/CA3031302A1/en not_active Abandoned
- 2017-07-28 HK HK18113925.3A patent/HK1254833B/en not_active IP Right Cessation
- 2017-07-28 SI SI201730093T patent/SI3319601T1/sl unknown
- 2017-07-28 MA MA42419A patent/MA42419B1/fr unknown
- 2017-07-28 ME MEP-2019-267A patent/ME03520B/me unknown
- 2017-07-28 HU HUE17742782A patent/HUE046590T2/hu unknown
- 2017-07-28 EA EA201990413A patent/EA201990413A1/ru unknown
- 2017-07-28 KR KR1020197002991A patent/KR20190034550A/ko not_active Withdrawn
- 2017-07-28 AU AU2017303346A patent/AU2017303346A1/en not_active Abandoned
- 2017-07-28 WO PCT/EP2017/069194 patent/WO2018020010A1/en not_active Ceased
- 2017-07-28 PT PT17742782T patent/PT3319601T/pt unknown
- 2017-07-28 SM SM20190628T patent/SMT201900628T1/it unknown
- 2017-07-28 ES ES17742782T patent/ES2751154T3/es active Active
- 2017-07-28 JP JP2019504740A patent/JP2019522030A/ja not_active Ceased
- 2017-07-28 RS RSP20191218 patent/RS59300B1/sr unknown
- 2017-07-28 HR HRP20191798TT patent/HRP20191798T1/hr unknown
- 2017-07-28 LT LT17742782T patent/LT3319601T/lt unknown
- 2017-07-28 DK DK17742782T patent/DK3319601T3/da active
- 2017-07-28 BR BR112019001178-1A patent/BR112019001178A2/pt not_active IP Right Cessation
-
2018
- 2018-03-26 US US15/935,695 patent/US10117854B2/en not_active Expired - Fee Related
- 2018-09-18 US US16/134,144 patent/US10328059B2/en not_active Expired - Fee Related
-
2019
- 2019-01-24 IL IL264460A patent/IL264460B/en active IP Right Grant
- 2019-11-18 CY CY20191101208T patent/CY1122348T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MA42419A (fr) | 2018-05-16 |
| US20180214417A1 (en) | 2018-08-02 |
| PL3319601T3 (pl) | 2020-06-29 |
| MA42419B1 (fr) | 2019-11-29 |
| IL264460B (en) | 2021-06-30 |
| DK3319601T3 (da) | 2019-11-18 |
| EP3275439A1 (en) | 2018-01-31 |
| BR112019001178A2 (pt) | 2019-04-30 |
| US20190070150A1 (en) | 2019-03-07 |
| CA3031302A1 (en) | 2018-02-01 |
| WO2018020010A1 (en) | 2018-02-01 |
| HK1254833B (en) | 2020-05-22 |
| JP2019522030A (ja) | 2019-08-08 |
| CY1122348T1 (el) | 2021-01-27 |
| RS59300B1 (sr) | 2019-10-31 |
| ES2751154T3 (es) | 2020-03-30 |
| EP3319601A1 (en) | 2018-05-16 |
| LT3319601T (lt) | 2019-11-11 |
| SMT201900628T1 (it) | 2020-01-14 |
| US10117854B2 (en) | 2018-11-06 |
| KR20190034550A (ko) | 2019-04-02 |
| PT3319601T (pt) | 2019-09-18 |
| HRP20191798T1 (hr) | 2019-12-27 |
| HUE046590T2 (hu) | 2020-03-30 |
| EP3319601B1 (en) | 2019-08-28 |
| US10328059B2 (en) | 2019-06-25 |
| AU2017303346A1 (en) | 2019-01-31 |
| ME03520B (me) | 2020-04-20 |
| IL264460A (en) | 2019-02-28 |
| SI3319601T1 (sl) | 2019-11-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1124368T1 (el) | Μεθοδοι αυξησης της τονικης αναστολης και θεραπειας του συνδρομου angelman | |
| MX373045B (es) | Inhibidores de mdm2 y metodos terapeuticos que utilizan el mismo. | |
| MX380252B (es) | Crenezumab para usarse en el tratamiento de enfermedad de alzheimer. | |
| MX373373B (es) | Inhibidores de desmetilasa-1 específica de lisina. | |
| MX2017014191A (es) | Metodos de tratamiento de una enfermedad neurodegenerativa. | |
| DOP2017000111A (es) | Inhibidor de cinasa aurora a | |
| JOP20210050A1 (ar) | معدلات تعبير pnpla3 | |
| MX2017006464A (es) | Combinaciones de inhibidor de tlr e inhibidor de tirosina cinasa de bruton. | |
| WO2019173795A3 (en) | Reduction of er-mam-localized app-c99 and methods of treating alzheimer's disease | |
| EA201891340A1 (ru) | Лечение рака с использованием 2-дезокси-2-фтор-l-фукозы в комбинации с ингибитором контрольных точек | |
| MX2017004618A (es) | Inhibidores de la biosintesis de sulfato de heparano para el tratamiento de enfermedades. | |
| EA201791110A1 (ru) | Сублингвальное введение рилузола | |
| TW201713333A (en) | Methods of treating a neurodegenerative disease | |
| EP3449001A4 (en) | INHIBITION OF MIR-22-MIRNA BY APT-110 | |
| BR112017000730A2 (pt) | derivados de pirrolidinona como inibidores de metap-2 | |
| AR112144A1 (es) | Compuestos para el tratamiento del sarcoma | |
| MX2020008195A (es) | Compuestos para el tratamiento del dolor. | |
| MX374458B (es) | Compuestos de triaminopirimidina útiles para evitar o tratar la malaria. | |
| CY1122348T1 (el) | Μεθοδος για την θεραπευτικη αντιμετωπιση της ηπατικης εγκεφαλοπαθειας | |
| PL3285755T3 (pl) | Chlorowodorek kreatyny do leczenia choroby Huntingtona | |
| MX2016008968A (es) | Compuestos organicos. | |
| PH12017501955A1 (en) | Tetrahydrofurane-fused aminohydrothiazine derivatives which are useful in the treatment of alzheimer`s disease | |
| CL2020000586A1 (es) | Moduladores de la expresión de enac. | |
| LT3897578T (lt) | Ly3154207 dozavimo režimai gydant dopaminerginius cns sutrikimus | |
| MX384394B (es) | Compuesto para uso en la prevención y tratamiento de enfermedades neurodegenerativas. |